EMA Authorised: Xydalba (dalbavancin hydrochloride) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The EMA authorised Xydalba (dalbavancin hydrochloride) for soft tissue infections, including acute bacterial skin and skin structure infections, in the European…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infections

Drugs mentioned

• Xydalba (dalbavancin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Soft Tissue Infections;Skin Diseases, Bacterial. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 20/11/2025